German national T-Cell Lymphoma Registry and Biobank of the German Lymphoma Alliance (GLA) and Ostdeutsche Studiengruppe für Hämatologie und Onkologie (OSHO)

German national T-Cell Lymphoma Registry and Biobank of the German Lymphoma Alliance (GLA) and Ostdeutsche Studiengruppe für Hämatologie und Onkologie (OSHO) - T-NHL-R

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00030561

Enrollment

600

Registered

2023-03-16

Start date

2022-10-21

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C86 C84

Interventions

Group 1: Pro- and retrospective registration of all patients with histologically confirmed T-cell lymphoma 18 years or older at the time of inclusion.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: = 18 yrs, Diagnosis of MTCL, Informed consent

Exclusion criteria

Exclusion criteria: < 18 yrs, no dagnosis of MTCL, no informed consent

Design outcomes

Primary

Measure	Time frame
disease and treatment characteristica of patients with t-cell lymphomas (remission status, relapse incidence, time to relapse, progression free survival, overall survival)	—

Secondary

Measure	Time frame
Clinical Registry: Frequency distribution of patient factors (age, height, weight, sex, comorbidities, Barthel index, HCT-CI) and comparison of frequencies with population-based tumor registry data; disease characteristics (histologic T-NHL subtypes, Ann Arbor stage, organs affected, risk factors such as IPI), diagnostic and treatment modalities at initial diagnosis and relapse (diagnostics performed, type and sequence of therapies, chemotherapy regimen and dose; Indication, time in therapy sequence and dose of radiotherapy, type and timing of staging); treatment outcome (remission status, recurrence incidence, time to recurrence, progression-free survival, overall survival); Frequency distribution of quality-of-life parameters at diagnosis, on therapy, and during follow-up (QLQ30, NCCN_FACT-FLYMSI-18, MDACC-Fatique Inventory, pro-CTC-AH, Scindex-29, VAS-scale pruritus); complications at diagnosis and on therapy (complications CTC-AE =3, SAEs). Reference pathology: recording the rate of reference pathology review. Consultation service: recording of frequency and standardized assessment 6 months after consultation. Biomaterial bank: recording of completeness and quality of biomaterials and accompanying data; recording of projects performed with biomaterials.	—

Measure

Time frame

Clinical Registry: Frequency distribution of patient factors (age, height, weight, sex, comorbidities, Barthel index, HCT-CI) and comparison of frequencies with population-based tumor registry data; disease characteristics (histologic T-NHL subtypes, Ann Arbor stage, organs affected, risk factors such as IPI), diagnostic and treatment modalities at initial diagnosis and relapse (diagnostics performed, type and sequence of therapies, chemotherapy regimen and dose; Indication, time in therapy sequence and dose of radiotherapy, type and timing of staging); treatment outcome (remission status, recurrence incidence, time to recurrence, progression-free survival, overall survival); Frequency distribution of quality-of-life parameters at diagnosis, on therapy, and during follow-up (QLQ30, NCCN_FACT-FLYMSI-18, MDACC-Fatique Inventory, pro-CTC-AH, Scindex-29, VAS-scale pruritus); complications at diagnosis and on therapy (complications CTC-AE =3, SAEs). Reference pathology: recording the rate of reference pathology review. Consultation service: recording of frequency and standardized assessment 6 months after consultation. Biomaterial bank: recording of completeness and quality of biomaterials and accompanying data; recording of projects performed with biomaterials.

—

Countries

Germany

Contacts

Public ContactThomas Weber

Martin-Luther-Universität Halle-WittenbergUniversitätsklinikum Halle (Saale)

tnhl-register@uk-halle.de0345-557-3033

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 11, 2026